A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?
- DOI
- 10.1080/13543784.2020.1839047
- Published
- 2020-11-11
- Container
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/13543784.2020.1839047,
title = {A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?},
author = {Dario Doller and Anton Bespalov and Rob Miller and Malgorzata Pietraszek and Mikhail Kalinichev},
year = {2020},
journal = {Expert Opinion on Investigational Drugs},
doi = {10.1080/13543784.2020.1839047},
url = {https://doi.org/10.1080/13543784.2020.1839047}
}RIS
TY - JOUR TI - A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model? AU - Dario Doller AU - Anton Bespalov AU - Rob Miller AU - Malgorzata Pietraszek AU - Mikhail Kalinichev PY - 2020 JO - Expert Opinion on Investigational Drugs DO - 10.1080/13543784.2020.1839047 UR - https://doi.org/10.1080/13543784.2020.1839047 ER -
APA
Doller, D., Bespalov, A., Miller, R., Pietraszek, M., & Kalinichev, M. (2020). A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2020.1839047
Source records
- crossref · retrieved 2026-09-25T20:56:33.679Z